The Run Isn't Over for This Booming Biotech
Few stocks in any sector have had the kind of thriving 2013 that NPS Pharmaceuticals has enjoyed. This biotech stock's up more than 200% year-to-date after receiving approval from the Food and Drug Administration late last year for Gattex, its orphan drug treatment for the rare condition small bowel syndrome, or SBS. Gattex has gotten off to a good start in the first six months of the year, opening up a small but solid patient base as NPS looks to get this rising star going.
It's just the start for Gattex: NPS is hoping the drug can catch on abroad as well, and even conservative peak sales estimates show that this drug has plenty of room to run. But considering this stock's astronomical rise in 2013, have investors who overlooked this stock through most of 2013 missed their chance at big gains?
Fortunately, NPS Pharmaceuticals has plenty of momentum going forward-momentum that could carry shares even higher in the future. In the video below, Fool contributor Dan Carroll tells you what to look for out of NPS in coming quarters -- and how this stock's on pace to keep rising higher over the long term.
Look no further than NPS to see how the boom-or-bust biotech sector can light up any investor's portfolio. However, to achieve real financial freedom, the best investment strategy is to pick great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" not only shares stocks that could help you build long-term wealth, but also winning strategies that every investor should know. Click here to grab your free copy today.
The article The Run Isn't Over for This Booming Biotech originally appeared on Fool.com.
Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.